Ectosense

ectosense.com

Ectosense is a funded Health-Tech startup on a mission to restore the sleep of the one billion people that suffer from a sleep disorder. We leverage the best techniques in micro-electronics, biomedical signal processing and data science to bring products that are vastly more elegant and effective.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

TRIALCARD LAUNCHES ENGAGE HCP

TrialCard | August 31, 2021

news image

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement servi...

Read More

Business Insights

INDEX PHARMACEUTICALS STRENGTHENS THE CLINICAL DEVELOPMENT ORGANIZATION IN PREPARATION OF THE START OF THE PHASE III STUDY CONCLUDE WITH COBITOLIMOD

InDex Pharmaceuticals | August 23, 2021

news image

InDex Pharmaceuticals Holding AB today announced that two new employees have been appointed in the clinical development organisation in preparation of the start of the phase III study CONCLUDE with cobitolimod. Anders Bröijersén is joining InDex as Senior Medical Director Clinical Operations and Johan Levin as Project Manager Clinical Operations. Anders Bröijersén is a medical doctor and PhD with 15 years of experience in Clinical Development...

Read More

Research

ETHYPHARM TO ACQUIRE ALTAN PHARMA, ALLOWING IT TO ENTER THE SPANISH MARKET AND EXPAND ITS CRITICAL CARE PORTFOLIO AND R&D PIPELINE.

Ethypharm | June 19, 2021

news image

Ethypharm reports today that it has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company that develops, manufactures and markets injectable medicines for hospital use. On account of the strong presence of Altan Pharma in Spain, Ethypharm will reach full commercial coverage of the main 5 European markets after shutting, which is expected in the second half of 2021. Ethypharm will likewise profit with an enlarged portfolio of great hospital...

Read More

PHARMACY MARKET, PHARMA TECH

PRESCRYPTIVE HEALTH PARTNERS WITH LILLY ON FIRST-TO-MARKET VALUE-BASED PROGRAM TO STABILIZE INSULIN PRICING

Prescryptive Health | December 16, 2022

news image

Prescryptive Health, a healthcare technology company on a mission to rewrite the script for the U.S. pharmaceutical market, today announced a partnership with Eli Lilly and Company on a new and first-to-market subscription model to help lower costs for people who pay for their Lilly insulin through their employer-sponsored benefits. Through a flat, per-member, per-month subscription fee, employers can offer insulin to their employees with predictable, affordable, and transparent costs. This uniq...

Read More
news image

Pharmacy Market

TRIALCARD LAUNCHES ENGAGE HCP

TrialCard | August 31, 2021

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement servi...

Read More
news image

Business Insights

INDEX PHARMACEUTICALS STRENGTHENS THE CLINICAL DEVELOPMENT ORGANIZATION IN PREPARATION OF THE START OF THE PHASE III STUDY CONCLUDE WITH COBITOLIMOD

InDex Pharmaceuticals | August 23, 2021

InDex Pharmaceuticals Holding AB today announced that two new employees have been appointed in the clinical development organisation in preparation of the start of the phase III study CONCLUDE with cobitolimod. Anders Bröijersén is joining InDex as Senior Medical Director Clinical Operations and Johan Levin as Project Manager Clinical Operations. Anders Bröijersén is a medical doctor and PhD with 15 years of experience in Clinical Development...

Read More
news image

Research

ETHYPHARM TO ACQUIRE ALTAN PHARMA, ALLOWING IT TO ENTER THE SPANISH MARKET AND EXPAND ITS CRITICAL CARE PORTFOLIO AND R&D PIPELINE.

Ethypharm | June 19, 2021

Ethypharm reports today that it has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company that develops, manufactures and markets injectable medicines for hospital use. On account of the strong presence of Altan Pharma in Spain, Ethypharm will reach full commercial coverage of the main 5 European markets after shutting, which is expected in the second half of 2021. Ethypharm will likewise profit with an enlarged portfolio of great hospital...

Read More
news image

PHARMACY MARKET, PHARMA TECH

PRESCRYPTIVE HEALTH PARTNERS WITH LILLY ON FIRST-TO-MARKET VALUE-BASED PROGRAM TO STABILIZE INSULIN PRICING

Prescryptive Health | December 16, 2022

Prescryptive Health, a healthcare technology company on a mission to rewrite the script for the U.S. pharmaceutical market, today announced a partnership with Eli Lilly and Company on a new and first-to-market subscription model to help lower costs for people who pay for their Lilly insulin through their employer-sponsored benefits. Through a flat, per-member, per-month subscription fee, employers can offer insulin to their employees with predictable, affordable, and transparent costs. This uniq...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us